text,gold_label,crowd_label,conf0,conf1
mn hypertens addit doubl blood mn increas risk hypertens numnum3 numnum3 numnum3 fold women men particip respect adjust covari,1,1,0.0,1.0
anthracyclin cardiotox cumul anthracyclin dose num2 week lvef 3dgl tnt predictor later develop cardiotox univari logist regress,1,1,0.0,1.0
ritonavir/rtv death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,0,0.8046,0.1954
aspirin death low dose aspirin asa use associ wide rang advers side effect upper gastrointestin gi tract rang troublesom symptom without mucos lesion seriou toxic includ ulcer gi bleed perfor even death,1,1,0.2093,0.7907
ribavirin chronic hepat c. liver histolog chronic hepat c patient relaps not respond convent interferon ribavirin therapi,0,0,1.0,0.0
ecstasi weight loss depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,1,0.0,1.0
estrogen rhabdoid tumor present studi investig express estrogen receptor er six malign rhabdoid tumor mrt cell line,0,0,0.8072,0.1928
morphin delirium opioid rotat morphin fentanyl may effect allevi delirium pain cancer patient morphine-induc delirium,1,1,0.2072,0.7928
methylen blue toxicosi male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,1,0.0,1.0
selenium hiv-infect investig effect daili selenium supplement cd4 cell count viral load pregnanc outcom matern infant mortal among num3 hiv-infect pregnant women,0,0,1.0,0.0
azdnum4/selumetinib colorect cancer identif predict marker respons mek1/num inhibitor selumetinib azdnum4 k-ras-mut colorect cancer,0,0,0.8116,0.1884
thalidomid inflammatori skin diseas thalidomid n-phtalimidoglutarimid initi use tranquil recent use manag sever inflammatori skin diseas,1,0,1.0,0.0
csnum4 cytotox csnum4 exhibit signific cytotox sever cancer cell type induc apoptot death hct-num cell dose- time-depend manner,1,1,0.0,1.0
docetaxel tumor th-num3 given num hr doxorubicin docetaxel increas dna damag apoptosi throughout tumor compar chemotherapi alon,1,0,0.8017,0.1983
aztreonam septicaemia random compar evalu teicoplanin plu aztreonam versu gentamicin plu piperacillin leukaem patient clinic diagnosi septicaemia undertaken,0,0,0.7979,0.202099999999999
ascorb acid toxic howev administr parenter ascorb acid num hour parenter chromat experiment studi not protect against renal damag parenter ascorb acid given num hour postparenter chromat increas toxic,1,1,0.2195,0.7805
barbitur hypotens refractori gcse often difficult treat tradit therapi barbitur induc hypotens respiratori depress prolong recoveri,1,1,0.0,1.0
anthracyclin cardiotox 3dgl seem good predictor futur develop anthracycline-induc cardiotox,1,1,0.0,1.0
melphalan rhabdomyosarcoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,1,0,1.0,0.0
betamethason labial adhes betamethason cream petroleum ointment safe effect primari therapi prepubert labial adhes,1,0,1.0,0.0
fentanyl postop pain thorac epidur numnum2 num ropivacain provid effect postop pain control combin fentanyl without motor block,1,0,1.0,0.0
nimodipin urticaria nimodipin versu terfenadin treatment physic stimulus-induc urticaria,1,0,0.8047,0.1953
chromium vi skin burn system toxic may occur follow ingest chromium vi salt chromium vi -induc skin burn inhal chromium vi occur occup,1,1,0.0,1.0
vitamin d. vitamin defici object describ preval vitamin defici investig determin plasma num2-hydroxyvitamin num2-ohd concentr high northern latitud countri,0,0,1.0,0.0
alcohol cardiac arrhythmia moreov alcohol abus produc cardiac arrhythmia hypertens cardiomyopathi stroke even sudden death,1,1,0.0,1.0
doxorubicin hcc use svm sever known hcc inhibitor geldanamycin alvespimycin hspnum2 inhibitor doxorubicin chemotherapi drug predict,1,0,1.0,0.0
dphm toxic data demonstr clear dose-depend acut toxic dphm,1,1,0.2127,0.7873
silicon granulomat pneumon specul hiv-num-infect patient may risk chronic progress granulomat pneumon due silicon inject year procedur owe shift level cell-medi immun,1,1,0.0,1.0
chromium vi allerg repeat topic exposur chromium vi may caus allerg contact dermat format chrome ulcer,1,1,0.0,1.0
simvastatin ischem stroke simvastatin acut phase ischem stroke safeti efficaci pilot trial,0,0,1.0,0.0
gatifloxacin bacteri kerat gatifloxacin moxifloxacin vitro suscept comparison levofloxacin ciprofloxacin ofloxacin use bacteri kerat isol,0,0,1.0,0.0
copper toxic environment impact associ resourc deplet human toxic mainli associ cobalt copper nickel thallium silver wherea ecotox potenti primarili associ cobalt copper nickel thallium silver,1,1,0.212,0.787999999999999
cilansetron corticotropin releas factor/crf ramosetron num num3 microg/kg pnumo found significantli suppress abnorm defec induc conditioned-fear stress cf restraint stress corticotropin releas factor crf num-ht rat mice effect potent alosetron cilansetron loperamid,1,0,0.787999999999999,0.212
ketanserin contract ring intact endothelium num-ht1-like-select agonist sumatriptan caus small contract -log ecnum2 num intrins activ numnum2 respect num-ht resist blockad num4 nm ketanserin antagon num3 nm methiothepin,0,0,1.0,0.0
dphm poison object studi investig dose-depend toxic dphm patient acut dphm poison,1,1,0.3879,0.6121
loratadin kerat num day use loratadin yield mean increas numnum2 point num3 kerat p .num3 mean increas numnum2 point num3 conjunctiv stain p .num3 mean decreas numnum2 second num2num tfbut p .num3 mean increas numnum2 point num2num ocular discomfort p .num2 vs baselin,1,1,0.1988,0.8012
cholesterol chd/coronari heart diseas mani popul high intak satur fat associ elev serum cholesterol concentr increas coronari heart diseas chd mortal,1,1,0.2156,0.7844
gossypolon toxic react easili electrophil aprot solvent regener gossypolon form dehydrogossypoldithian dehydrogossypoldithiolan display higher toxic kb cell,1,0,0.8131,0.1869
vitamin k epoxid alveolar hemorrhag hypothes patient treat coumarin alveolar hemorrhag associ vitamin k epoxid reductas vkorc1 cytochrom pnum3 cyp 2c9 cyp2c9 variant allel,1,1,0.1953,0.8047
iodin thyroid cancer amifostin radioprotect effect salivari gland high-dos radioact iodine-tr differenti thyroid cancer,0,0,1.0,0.0
iron iron defici athlet whose iron intak suffici num2num mg princip caus iron defici blood loss due menstruat,0,0,1.0,0.0
cyclosporin lichen planopilari short cours oral cyclosporin lichen planopilari,1,0,1.0,0.0
alcohol hiv-coinfect standard questionnair use collect basic demograph data region birth histori tb hiv-coinfect alcohol use antituberculosi treatment,0,0,1.0,0.0
estrogen hypertens examin heart rate variabl hrv respons estrogen replac therapi ert associ chang metabol variabl hypertens postmenopaus women,0,0,1.0,0.0
tunicamycin hepatoma furthermor down-regul cox-num express use cox-num inhibitor celecoxib increas tunicamycin-induc apoptosi concomit up-regul pro-apoptot transcript factor chop gaddnum3 down-regul b-cell lymphoma num/bcl-num-associ x protein bcl-num/bax ratio suggest inhibit cox-num sensit human hepatoma cell er stress-induc apoptosi,1,0,0.8115,0.1885
thallium myocardi infarct twelv patient exercise-induc st-segment elev without prior myocardi infarct electrocardiograph evid left ventricular hypertrophi left bundl branch block underw thallium-num3 tomographi immedi exercis num hour later,0,0,1.0,0.0
txb2 tnfa concentr il-1b tnfa remain almost stabl group b wherea concentr txb2 reduc not significantli p numnum2,0,0,0.8248,0.1752
procarbazin medulloblastoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,0,1.0,0.0
glucos diabet effect konjac food blood glucos level patient diabet,0,0,0.8031,0.1969
pentachlorophenol poison human pentachlorophenol poison,1,1,0.208099999999999,0.7919
atra apl patient apl num2 num2 alon significantli sensit treatment atra patient num2 num2 addit cytogenet abnorm,0,0,0.7984,0.2016
melphalan medulloblastoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,0,1.0,0.0
sertindol ep eps-rel event compar placebo sertindol group,0,0,1.0,0.0
hydrocortison depress also strong relat mean daili hydrocortison dose psycholog morbid inum depress p numnum2 qol impair inum gener health percept sever measur physic function vital p numnum2,1,1,0.1939,0.8061
reboxetin attention-deficit/hyperact disord efficaci reboxetin adult attention-deficit/hyperact disord random placebo-control clinic trial,0,0,1.0,0.0
dapson dh describ num2-year-old chines woman develop dh num week dapson therapi pustular palmoplantar psoriasi,1,1,0.2078,0.7922
mn hypertens blood mn level associ increas risk hypertens repres sampl korean adult popul,1,1,0.0,1.0
zanamivir bronchospasm bronchospasm found num2 year old woman whose symptom disappear stop zanamivir without addit treatment,1,1,0.1972,0.8028
clozapin cardiomyopathi prompt case clozapine-rel pericard adolesc undertook retrospect chart review discov whether unrecogn case myocard pericard cardiomyopathi among children adolesc young adult treat clozapin,1,1,0.2121,0.7879
"num num'-oligoadenyl hcl/hairi cell leukemia ten patient hairi cell leukemia hcl seven patient b-cell chronic leukemia bcl studi intracellular num num'-oligoadenyl synthetas num,5oa activ mononuclear cell num h num2 h num2 h pentostatin administr",0,0,1.0,0.0
schiff base cancer anti-canc activ mutagen potenti novel copper ii quinolinon schiff base complex hepatocarcinoma cell,0,0,1.0,0.0
corticosteroid diseas although patient initi stabil therapi corticosteroid plasma exchang mitoxantron sever cognit impair persist eventu die sequela diseas,0,0,1.0,0.0
naftidrofuryl hypotens suggest naftidrofuryl might administ use complement convent hypotens therapi sinc act posit glaucomat optic nerv damag,0,0,1.0,0.0
glutamin tumor vitro evid depend tumor growth glutamin deter use clinic set,1,1,0.1924,0.8076
polyethylen glycol renal cell carcinoma polyethylen glycol conjug interleukin-num clinic immunolog effect patient advanc renal cell carcinoma,1,0,0.805999999999999,0.194
morphin cancer twenty-on consecut cancer patient morphine-induc delirium underw opioid rotat fentanyl,0,0,1.0,0.0
propofol diabet random single-blind placebo-control prospect studi serum troponin concentr ctni baselin num num num2 num2 num2 num2 h postop measur isoflurane/sufentanil propofol/sufentanil anesthesia without ripc three num-min period intermitt left upper arm ischemia num min reperfus non-diabet patient n num2 three-vessel coronari arteri diseas clinicaltrialsnumgov nctnum5,0,0,1.0,0.0
dmba tumor vorozol like ovariectomi almost complet reduc tumor growth dmba-induc mammari carcinoma model rat,0,0,0.6016,0.3984
carbon toxic understand toxic carbon nanotub environ crucial control nanomateri produc process assess health risk human review,1,1,0.1891,0.8109
pregabalin somnol pregabalin well toler common advers event dizzi somnol,1,1,0.0,1.0
sertralin depress one hundr patient major depress discontinu fluoxetin side effect enrol multicent open num-week studi sertralin,0,0,1.0,0.0
mycophenol acid gi complic unrestrict literatur search num4-januari num4 perform medlin embas use follow key word drug-drug interact enteric-co mycophenol acid gi complic mycophenol mofetil solid organ transplant proton pump inhibitor includ individu agent within class,0,0,0.7945,0.2055
roflumilast copd placebo-control double-blind parallel-group multicent phase num studi patient chines malay indian ethnic n num3 sever sever copd random num num receiv either roflumilast num3 e_g daili placebo num2 week,0,0,0.8174,0.1826
sorafenib toxic combin sorafenib bevacizumab substanti toxic minim efficaci patient previous treat metastat breast cancer,1,1,0.3726,0.6274
chromium poison smaller dose ascorb acid enumg. num2 g intraven not toxic dose probabl not reduc mortal system chromium poison,1,1,0.3968,0.6032
hbeag hepat b. predict respons peginterferon alpha-2a lamivudin two combin hbeag-neg chronic hepat b,0,0,1.0,0.0
azathioprin angioedema num2-year-old woman num yr histori chronic recurr urticari vascul angioedema refractori convent treatment includ glucocorticosteroid h1 h2 blocker nonsteroid antiinflammatori agent methotrex hydroxychloroquin dapson azathioprin intraven gamma globulin plasma exchang success treat interferon alpha 2a,1,0,1.0,0.0
dopamin impuls control disorder/icd patient parkinson 's diseas pd impuls control disord icd result dopaminerg medic use particularli dopamin agonist daa,1,1,0.1922,0.8078
medroxyprogesteron acetate/mpa tumor aim studi investig effect high-dos medroxyprogesteron acet mpa tumor necrosi factor-alpha tnf-alpha releas patient chemotherapy-induc neutropenia,0,0,1.0,0.0
pioglitazon diabet cumul incid diabet num2num pioglitazon num2num placebo unadjust hr numnum3 num2 ci numnum3-numnum3 p numnum3,1,1,0.1955,0.8045
sodium chlorid nephropathi result studi not suggest hydrat sodium bicarbon superior hydrat sodium chlorid prevent contrast medium-induc nephropathi patient moder sever chronic kidney diseas undergo coronari angiographi,0,0,1.0,0.0
daunorubicin cytotox cytotox nk-num2 daunorubicin cytarabin against kg1 measur use chromium-releas assay flow cytometri clonogen assay,1,1,0.3795,0.6205
tacrolimu mpa total mpa concentr increas num month not patient tacrolimu,0,0,1.0,0.0
erythromycin gastrointestin upset two out num2 peopl oral erythromycin num out num2 placebo report minor gastrointestin upset,1,1,0.1932,0.8068
formoterol copd lung deposit efficaci inhal formoterol patient moder sever copd,0,0,1.0,0.0
glucos obes broad-rang effect fxe may due uniqu composit profil could use prevent metabol syndrom character obes insulin resist glucos intoler hypertriglyceridemia elev blood pressur,0,0,1.0,0.0
silver toxic environment impact associ resourc deplet human toxic mainli associ cobalt copper nickel thallium silver wherea ecotox potenti primarili associ cobalt copper nickel thallium silver,1,1,0.194,0.805999999999999
heparin bleed retrospect evalu effect heparin use thromboembol bleed complic implant heartmat ii left ventricular assist devic lvad,0,0,0.8164,0.1836
mn-dpdp/mangafodipir pancreat lesion assess accuraci magnet reson mr mangafodipir mn-dpdp identif focal solid pancreat lesion,0,0,1.0,0.0
iron iron defici high level physic activ express train volum experi not advers affect iron store higher control subject incid iron defici much lower control group,0,0,1.0,0.0
estrogen ht part almost work ht estrogen given primari focu despit fact progesteron import properti enhanc repair neurodegen traumat injuri central nervou system,0,0,1.0,0.0
h num num necrosi addit experiment perform test solut replac media num h result supernat quantifi num2 h. bak induc signific amount interleukin il- num tumor necrosi factor tnf moder amount c-reactiv protein crp il- num2 num2 h num num,0,0,1.0,0.0
lutein melanoma lutein not alter fibroblast melanoma cell viabil membran integr,0,0,1.0,0.0
levodopa fractur herein report case young woman suffer recurr metatars fractur context levodopa-tr early-onset parkinson 's diseas,1,1,0.184,0.816
somatostatin hypothalam clarifi pathogenesi underli alter six obes patient num male num femal age num2-num2 yr bmi num2num +/- num unrestrict diet studi effect num day ghrh pretreat num micrograms/kg iv day acut somatotrop respons neurohormon administ alon combin arginin arg num g/kg iv infus num num2 min like inhibit releas hypothalam somatostatin,0,0,0.7936,0.2064
indomethacin necrot enterocol recent exposur antenat indomethacin associ necrot enterocol num num2 ci num-num,1,1,0.0,1.0
num-hydroperoxycyclophosphamid chromosom abnorm chromosom abnorm patient treat num-hydroperoxycyclophosphamide-purg autolog bone marrow transplant,1,1,0.3949,0.6051
timolol poag num-month multicent random open-label studi num3 patient poag oh whose iop not control timolol num bnuminumd enrol,0,0,1.0,0.0
l-dopa neuroblastoma effect three non-myelotox cancer drug growth neuroblastoma cell investig vitro vivo dihydroxyphenylalanin l-dopa drug select toxic melanoma cell dl-buthionin sulphoximin bso drug radiosensit effect tamoxifen drug use treatment human mammari carcinoma,0,0,1.0,0.0
pomalidomid myelofibrosi pomalidomid therapi effect allevi anemia myelofibrosi examin relationship plasma cytokine/chemokin level respons treatment pomalidomid,1,0,1.0,0.0
pravastatin non-insulin-depend diabet mellitu multin studi effect low-dos pravastatin patient non-insulin-depend diabet mellitu hypercholesterolemia,0,0,1.0,0.0
haloperidol catalepsi thpp-num display significantli fewer preclin advers event assay measur prolactin secret catalepsi weight gain contrast typic atyp antipsychot haloperidol olanzapin,1,1,0.3907,0.6093
estrogen neuropath pain broad modul neuropath pain state select estrogen receptor beta agonist,0,0,1.0,0.0
ranirestat neuropathi trial subject newli diagnos neuropathi along identif object biomarkers/measur efficaci critic identifi real valu effect ranirestat,0,0,1.0,0.0
clomipramin sexual dysfunct index term includ sexual dysfunct antidepress select serotonerg reuptak inhibitor fluoxetin sertralin paroxetin fluvoxamin clomipramin buspiron nefazodon bupropion cyproheptadin amantadin yohimbin central nervou system stimul,0,0,1.0,0.0
metformin polycyst ovari syndrome/pco aim re-evalu whether metformin may reduc late miscarriage/preterm deliveri pre-eclampsia gestat diabet women polycyst ovari syndrom pco,0,0,1.0,0.0
paclitaxel/ptx cancer five cancer cell line resist irinotecan snnum2 paclitaxel ptx etoposid vpnum2 oxaliplatin oxa gemcitabin gem respect establish parent gastric cancer cell line ocum-2m name ocum-2m/snnum2 ocum-2m/ptx ocum-2m/vpnum2 ocum-2m/oxa ocum-2m/gem,0,0,1.0,0.0
octreotid sleepi improv indic oxygen desatur sleep qualiti subject sleepi improv num month octreotid,1,1,0.3917,0.6083
olanzapin bodyweight gain bodyweight gain common advers effect although somewhat less report olanzapin,1,1,0.3912,0.6088
atp/adenosin triphosph syncop sought investig patient syncop relationship document paroxysm atrioventricular block avb unknown mechan avb induc adenosin triphosph atp inject,0,0,0.7839,0.2161
creatinin cancer moreov mean valu 8ohdg random urinari sampl cancer patient significantli higher healthi individu numnum2 +/- numnum2 versu numnum2 +/- numnum2 mumol/mol creatinin p numnum3 sampl taken therapi onset numnum2 +/- numnum2 p numnum3 versu healthi individu numnum2 +/- numnum2 p numnum3 versu healthi individu,0,0,0.8167,0.1833
sorbitol lactic acidosi anoth featur turp syndrom hyperglycaemia lactic acidosi caus massiv absorpt sorbitol,1,1,0.0,1.0
indoxyl sulfat glomerular sclerosi previous demonstr indoxyl sulfat stimul factor progress glomerular sclerosi urem rat,1,1,0.1878,0.8122
amiodaron pneumonia object studi assess diagnost accuraci pcle amiodarone-rel pneumonia amr-ip,1,1,0.1971,0.8029
triglycerid coronari heart diseas moder hypertriglyceridemia fairli common elev triglycerid risk factor coronari heart diseas,1,1,0.202,0.797999999999999
aspirin ulcer low dose aspirin asa use associ wide rang advers side effect upper gastrointestin gi tract rang troublesom symptom without mucos lesion seriou toxic includ ulcer gi bleed perfor even death,1,1,0.1987,0.8013
nevirapine/nvp death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,0,1.0,0.0
halothan liver diseas num2 overt icter hepat case num2 num thought true overt icter posttransfus hepat icteru caus reason num2 case seven neonat jaundic four hemolyt anemia one radiat hepat one halothane-induc hepat two case exclud chronic liver diseas diagnos imag procedur despit serum alt normal rang transfus,0,0,1.0,0.0
mpa cholelithiasi find consist increas incid gallbladd diseas relat high-progesteron state suggest mpa may caus agent cholelithiasi,1,1,0.0,1.0
gentamicin septicaemia compar efficaci safeti studi teicoplanin plu aztreonam versu gentamicin plu piperacillin haematolog oncolog patient clinic diagnos septicaemia,0,0,1.0,0.0
nicotin nausea investig factor influenc effect address three question num intens dizzi nausea nin unsteadi depend nicotin dosag,0,1,0.207,0.792999999999999
mtx acceler nodulosi acceler nodulosi occur exclus treatment mtx doubl blind studi,1,1,0.0,1.0
ici num3numnum3 inflammatori result show tamoxifen raloxifen ici num3numnum3 induc anti-inflammatori respons acut model mous rat microgli cell,1,0,0.6214,0.3786
calcium poison taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0,0.8194,0.1806
olopatadin at active-treat group improv clinic score tear itch pronounc compar at group although day-num2 differ tear score olopatadin at group not statist signific,0,0,1.0,0.0
tpa skin-tumor promot addit compound num num2 exhibit inhibitori effect skin-tumor promot vivo two-stag mous skin carcinogenesi test base num num2-dimethylbenz anthracen dmba initi tpa promot,1,1,0.3931,0.6069
taxan breast cancer carboplatin gemcitabin cg combin activ unselect anthracycline/taxan pretreat metastat breast cancer patient carri out phase ii studi evalu activ cg combin pretreat metastat tnbc patient,0,0,1.0,0.0
silic tuberculosi increas incid tuberculosi observ among silic worker could explain accumul iron complex dust particl lung made avail dormant mycobacteria virul factor,1,1,0.3877,0.6123
erlotinib glioblastoma recent perform analysi tumor obtain phase trial erlotinib patient glioblastoma multiform gbm common malign brain tumor adult,0,0,1.0,0.0
terbinafin tinea pedi clinic studi conduct determin efficaci terbinafin cream sever case tinea pedi,0,0,1.0,0.0
iron athlet iron statu femal endur athlet non-athlet,0,0,1.0,0.0
teicoplanin neutropenia risk factor vre colon paediatr oncolog patient includ durat neutropenia durat antibiot therapi exposur ceftazidim amikacin teicoplanin number antibiot use,0,0,1.0,0.0
paracetamol hypotens mechan paracetamol-induc hypotens critic ill patient prospect observ cross-ov studi,1,1,0.0,1.0
mibefradil tacrolimu toxic tacrolimu toxic due drug interact mibefradil patient liver transplant,1,1,0.0,1.0
azdnum4 crc aim studi develop character predict biomark respons mek1/num inhibitor azdnum4 crc order maxim clinic util agent,0,0,1.0,0.0
methotrex pancytopenia sever pancytopenia patient take low dose methotrex probenecid,1,1,0.0,1.0
angiotensin hypertens thirty-two patient essenti hypertens treat angiotensin receptor blocker monotherapi random receiv num mg amlodipin n=num2 num mg perindopril n=num2 daili morn num2 week,0,0,1.0,0.0
bisphosphon bone diseas phase iii studi compar efficaci new potent bisphosphon ibandron placebo intraven i.v therapi metastat bone diseas due breast cancer,0,0,1.0,0.0
ciprofloxacin bacteri kerat gatifloxacin moxifloxacin vitro suscept comparison levofloxacin ciprofloxacin ofloxacin use bacteri kerat isol,0,0,1.0,0.0
oxygen critic ill. elev system oxygen deliveri treatment critic ill patient,0,0,1.0,0.0
iron cytotox iron ion produc cytotox toward kind cell depend concentr,1,1,0.0,1.0
suramin igf result suggest suramin-induc igf suppress could one possibl mechan suramin action,1,1,0.3948,0.6052
iodin thyroid cancer assess effect amifostin salivari gland radioact iodine-tr differenti thyroid cancer,0,0,1.0,0.0
tetracyclin infect recommend manag infect consist drainag antimicrobi therapi tetracyclin clindamycin fluoroquinolon,1,0,1.0,0.0
propofol unconsci recent studi anesthetic-induc unconsci human focus predominantli intraven drug propofol identifi anterior domin alpha rhythm frontal phase-amplitud coupl pattern neurophysiolog marker,1,1,0.0,1.0
vitamin d. breast cancer studi examin possibl interact synthet vitamin analogu cbnum4 two known mediat apoptosi tnfalpha ceramid mcf-num tnum2d hsnum3t breast cancer cell,0,0,1.0,0.0
delta num -tetrahydrocannabinol/thc anxieti activ principl marijuana delta num -tetrahydrocannabinol thc shown wide therapeut applic number import medic condit includ pain anxieti glaucoma nausea emesi muscl spasm wast diseas,1,0,1.0,0.0
salmeterol asthma small signific increas respiratory-rel death num2 vs num2 rr numnum2 num2 ci numnum2 numnum2 asthma-rel death num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 combin asthma-rel death life-threaten experi num2 vs num2 rr numnum2 num2 ci numnum2 numnum2 subject receiv salmeterol vs placebo,1,1,0.3777,0.6223
steroid inflammatori diseas numnum2 tacrolimu ointment safe effect use anterior segment inflammatori diseas refractori steroid,0,0,0.8164,0.1836
pcp pneumonia primari secondari p. carinii pneumonia prophylaxi discontinu num2 patient num first episod pcp occur num month no episod record median follow-up num2 month,0,0,1.0,0.0
pdnum5 adhes enhanc adher elicit num2 -hete bnum2fnum2 cell could antagonis focal adhes kinas fak inhibitor num2 fak inhibitor pdnum5 extracellular signal-regul kinas erk inhibitor,0,0,0.7958,0.2042
steroid ulcer two infant acut life-threaten complic duoden ulcer follow steroid administr describ,1,1,0.0,1.0
perindopril hypertens conclus result suggest angiotensin i-convert enzym inhibitor perindopril superior calcium channel blocker amlodipin reduc vascular endotheli dysfunct co-administ angiotensin receptor blocker patient essenti hypertens,0,0,1.0,0.0
furosemid thrombocytopenia base observ case report clinician readili consid furosemid potenti caus thrombocytopenia,1,1,0.0,1.0
tamoxifen uterin cancer thirty-nin num2 develop uterin cancer num2 month discontinu tamoxifen,1,0,0.8117,0.1883
mpa mpa high csa c2 associ elev ggt probabl cholestat effect explain increas mpag-to-mpa ratio,0,0,0.7843,0.2157
budesonid dermat allerg contact dermat respons budesonid reactiv inhal allergen,1,1,0.0,1.0
cholesterol non-insulin-depend diabet mellitus/niddm multin num2-week random double-blind placebo-control studi evalu efficaci safeti low-dos pravastatin num3 patient non-insulin-depend diabet mellitu niddm hypercholesterolemia serum total cholesterol concentr num-num mmol/l num3 num3 mg/dl,0,0,1.0,0.0
perindopril hypertens thirty-two patient essenti hypertens treat angiotensin receptor blocker monotherapi random receiv num mg amlodipin n=num2 num mg perindopril n=num2 daili morn num2 week,0,0,1.0,0.0
fingolimod multipl sclerosi sever multipl sclerosi reactiv fingolimod num month natalizumab withdraw,1,1,0.2058,0.7942
acyl-coa adrp addit triacsin c potent inhibitor acyl-coa synthas num h decreas amount tg vldl-induc foam cell oleic acid-tr liver cell decreas amount adrp protein parallel indic amount adrp reduc regress lipid-stor cell,0,0,1.0,0.0
steroid hepat caution must exercis administr steroid patient underli chronic hbv infect prevent exacerb hepat,1,1,0.1991,0.8009
